China Focus: China strives for affordable cancer drugs

    Source: Xinhua| 2018-07-24 11:13:17|Editor: Liangyu
    Video PlayerClose

    BEIJING, July 24 (Xinhua) -- A breast cancer patient surnamed Zhou in a hospital in Chengdu, Sichuan Province, said she is grateful for the reduced costs of cancer drugs.

    Zhou said she used to pay over 30,000 yuan (4,500 U.S. dollars) each month for the drug Herceptin. "Since the price dropped and my insurance now reimburses the cost, I feel like a weight has been lifted off my shoulders."

    The cost and short supply of cancer drugs have been a longstanding public concern in China.

    To alleviate these concerns, the government has introduced policies to address the issue while experts have called on domestic pharmaceutical enterprises to invest more in research and innovation and make more cancer drugs available for the patients.

    PRICE REDUCED

    From May 1, import tariffs have been lifted on all common drugs including cancer drugs and cancer alkaloid-based drugs.

    This is one of the government's latest efforts to make medical care more affordable and accessible to citizens.

    In July 2017, the country included 15 tumor-targeting medicines into its list of medically insured drugs and reduced their prices. The list covers a majority of the most frequently used cancer drugs.

    Prices of some medicines have dropped remarkably. In Hunan Province, the price of each vial of Herceptin decreased from 17,600 yuan to 7,600 yuan, and the price of each vial of Fulvestrant, also used to treat breast cancer, dropped from 11,500 yuan to 4,800 yuan.

    The newly-formed State Medical Insurance Administration said it would further cut the price of cancer drugs on the list via public bidding and procurement.

    And medical insurance institutions and pharmaceutical enterprises should negotiate before more cancer medicines, currently not on the list, are included and covered by the insurance.

    Meanwhile, the State Drug Administration (SDA) is expediting the approval of cancer drugs. For example, the approval of the marketing of human papillomavirus (HPV) 9-valent vaccine was shortened to just eight days.

    According to Jiao Hong, head of the SDA, the administration will fast-track more imported cancer medicines for approval so these medicines can enter China one to two years earlier.

    INNOVATION NEEDED

    With the prices of cancer drugs substantially declining, demands are exploding nationwide, resulting in a shortage of some drugs in a few areas.

    "The key to minimizing cost and reliance on imported cancer drugs is to raise our capability in research and development," said Zeng Yixin, vice director of the National Health Commission.

    Data published by the National Cancer Center (NCC) showed that China saw 3.8 million new cases of malignant tumors and 2.3 million cancer-related deaths in 2014.

    "Such a large population of cancer patients cannot rely solely on imported cancer medicines," said Shi Yuankai, deputy director of NCC. "China must advance the innovation capacity of its own pharmaceutical enterprises to meet the demand."

    China has more than 4,000 pharmaceutical producers, of which over 90 percent produce generic drugs.

    With policies to encourage drug research and innovation in recent years, China is forging ahead to make innovative drugs.

    Independently developed domestic drugs, such as lung cancer-targeting drug Conmana and gastric cancer-targeting drug Apatinib, now offer a cheaper alternative to the more expensive imported drugs

    In June, HYML-122, a drug targeting acute myeloid leukemia, was approved by the SDA for a clinical trial. It was developed by a research team from Hefei Institute of Physical Science. If the trial is successful, the drug will be put into clinical use in five years.

    Liu Qingsong, the team leader, said they are striving to make cancer as controllable as chronic diseases like high blood pressure and diabetes. "Our goal is to enable cancer patients to live a normal and fulfilling life."

    TOP STORIES
    EDITOR’S CHOICE
    MOST VIEWED
    EXPLORE XINHUANET
    010020070750000000000000011100001373447391
    主站蜘蛛池模板: 澳门永久av免费网站| 欧美色图在线播放| 日本伦理电影网伦理在线电影| 亚洲综合无码一区二区| 中文字幕日本最新乱码视频| 毛片毛片免费看| 国产xxxxx| 2021国产成人精品国产| 忘忧草www日本| 久久精品国产四虎| 污污视频网站免费在线观看| 四虎影院海外永久| 欧美波霸影院在线观看| 天堂网在线最新版www| 久久一区二区三区免费播放| 精品女同一区二区三区在线| 国产精品99久久精品爆乳| www.色偷偷.com| 日本狂喷奶水在线播放212| 亚洲日韩中文字幕| 粗大的内捧猛烈进出视频| 国产亚洲高清不卡在线观看 | 一级毛片在线播放| 日韩精品无码一区二区三区| 亚洲熟妇av一区二区三区宅男 | 精品欧美军人同性videos| 国产孕妇孕交大片孕| 337p色噜噜| 天天操天天干天天透| 中文字幕不卡在线观看| 日韩亚洲欧美一区| 亚洲人成网网址在线看| 波多野结衣免费一区视频| 六月婷婷综合网| 菠萝蜜网站入口| 国产成人精品久久综合| 24小时在线免费视频| 大香伊蕉国产av| 久草福利资源站| 欧美综合天天夜夜久久| 免费人成无码大片在线观看|